Sistemic Ltd and QCMD Ltd (Quality Control for Molecular Diagnostics) announced today that the companies had entered into a cross-licensing agreement. The arrangement centres on Sistemic’s SistemQC™ technology which is widely used by companies developing cell-based therapies allowing characterisation of the cell products and development of potency assays for product release and QCMD’s proprietary informatics platform and characterised quality assurance materials.
Full Release: Click to read the full release